Breaking Finance News

Piperjaffray downgraded Alcobra Ltd (NASDAQ:ADHD) from Overweight to Neutral in a report released today.

Yesterday Alcobra Ltd (NASDAQ:ADHD) traded -53.64% lower at $2.51. The company’s 50-day moving average is $4.83 and its 200-day moving average is $4.53. With the last stock price close down -52.77% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was up over the average, with 1,624,270 shares of ADHD changing hands over the typical 92,709

Piperjaffray has downgraded Alcobra Ltd (NASDAQ:ADHD) from Overweight to Neutral in a report released on 9/30/2016.

Performance Chart

Alcobra Ltd (NASDAQ:ADHD)

With a total market value of $0, Alcobra Ltd has with a one year low of $2.00 and a one year high of $8.78 .

A total of 7 brokerages have issued a ratings update on Alcobra Ltd. Three analysts rating the company a strong buy, three analysts rating the company a buy, zero brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $12.71.

General Information About Alcobra Ltd (NASDAQ:ADHD)

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *